Earnings Feed
Start Free
Home/Filings/4/0001181431-10-003557
4//SEC Filing

Singh Nikhilesh N 4

Accession 0001181431-10-003557

CIK 0001178711other
View on SEC.govCompany Profile

Filed

Jan 18, 7:00 PM ET

Accepted

Jan 19, 6:17 PM ET

Size

11.8 KB

Accession

0001181431-10-003557

Insider Transaction Report

Form 4
Period: 2010-01-14
Transcept Pharmaceuticals IncTSPT
Singh Nikhilesh N
SVP & Chief Scientific Officer
Transactions
  • Award

    Employree Stock Option (right to buy)

    2010-01-14+47,300→ 47,300 total
    Exercise: $8.21Exp: 2020-01-14→ Common Stock (47,300 underlying)
  • Award

    Employee Stock Option (right to buy)

    2010-01-14+24,100→ 24,100 total
    Exercise: $8.21Exp: 2020-01-14→ Common stock (24,100 underlying)
Holdings

  • Common Stock

    (indirect: See footnote)
    36,709

  • Common Stock

    14,791

  • Common Stock

    (indirect: See footnote)
    295

  • Common Stock

    (indirect: See footnote)
    78,206
Footnotes (6)
  • [F1]This total includes 1,354 shares purchased on November 30, 2009 under the 2009 Employee Stock Purchase Plan.
  • [F2]Shares held directly by the Reporting Person's spouse.
  • [F3]Shares held directly by the Singh Family Trust (the "Family Trust") for which Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
  • [F4]Shares held directly by the Nikhilesh and Nikki Singh Revocable Trust (the "Revocable Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Revocable Trust except to the extent of his pecuniary interest therein.
  • [F5]The option vests in forty-eight equal monthly installments beginning February 14, 2010.
  • [F6]Fifty percent of the option vests upon approval by the U.S. Food and Drug Administration of Intermezzo(R) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than January 14, 2012.

Documents

1 file

Issuer

Transcept Pharmaceuticals Inc

CIK 0001178711

→
Entity typeother

Related Parties

1
  • filerCIK 0001454351

Filing Metadata

Form type
4
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 6:17 PM ET
Size
11.8 KB
View on SEC.gov